Related Experiment Video
Updated: May 22, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study
Christian Bischoff1, H Schreiber, A Bergmann
1Neurologische Gemeinschaftspraxis am Marienplatz, Department of Neurology, Technische Universität München, Burgstrasse 7, 80331, Muenchen, Germany. bischoff@profbischoff.de
Journal of Neurology
|April 25, 2012
Summary
Improving adherence to immunomodulatory therapy (IMT) in multiple sclerosis (MS) patients requires addressing patient-reported reasons for withdrawal, such as lack of efficacy and side effects. Enhancing the therapeutic setting, including physician empathy and nursing support, is crucial for better patient outcomes.
Area of Science:
- Neurology
- Immunology
- Patient Adherence Research
Background:
- Adherence to immunomodulatory therapy (IMT) remains a significant challenge for patients with multiple sclerosis (MS).
- Understanding patient-driven reasons for treatment interruption is vital for developing effective adherence strategies.
Purpose of the Study:
- To investigate the reasons behind MS patients' decisions to discontinue immunomodulatory therapies.
- To explore patients' willingness to restart therapy and identify barriers to re-initiation.
- To determine factors influencing adherence and patient expectations in MS management.
Main Methods:
- Analysis of data from 396 MS patients across 40 German outpatient centers who had stopped IMT.
- Collection of information on adherence, reasons for withdrawal, and willingness to restart therapy.
- Exploration of correlations between patient expectations, physician empathy, and the healthcare setting.
Main Results:
- 74.6% of patients independently decided to withdraw from IMT.
- Primary reasons for withdrawal included lack of efficacy (51.4%), side effects (58.1%), fatigue, and depression.
- Over half of the patients (51.8% of females, 48.9% of males) expressed willingness to restart IMT, citing conviction in therapy's impact and fear of injections as key factors.
Conclusions:
- Patient adherence to IMT in MS is influenced by perceived efficacy, side effects, and psychological factors.
- A supportive and individualized therapeutic environment, encompassing medical, organizational, and psychological aspects, is essential for improving adherence.
- Addressing patient concerns and fostering trust are critical for sustained treatment engagement in MS.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...